BPMC Blueprint Medicines Corp

  1. Stocks
  2. Healthcare
  3. NASDAQ: BPMC

Price (delayed)

$58.22

Market cap

$3.52B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$9.71

Enterprise value

$3.59B

Blueprint Medicines is a global precision therapy company that invents life-changing medicines for people with cancer and hematologic disorders. Applying an approach that is both precise and agile, the company ...

Highlights
BPMC's gross margin is up by 5% year-on-year and by 2.2% since the previous quarter
Blueprint Medicines's EPS has increased by 12% YoY but it has decreased by 3.9% QoQ
The net income has increased by 11% YoY but it has decreased by 4.2% QoQ
BPMC's debt has soared by 119% year-on-year
Blueprint Medicines's equity has shrunk by 53% YoY and by 20% QoQ
Sector: Healthcare
Industry: Biotechnology
Website: http://www.blueprintmedicines.com
Peers: OPK PACB ALDX

Key stats

What are the main financial stats of BPMC
Market
Shares outstanding
60.47M
Market cap
$3.52B
Enterprise value
$3.59B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
8.43
Price to sales (P/S)
17.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.53
Earnings
Revenue
$204.59M
EBIT
-$552.48M
EBITDA
-$530.16M
Free cash flow
-$502.86M
Per share
EPS
-$9.71
Free cash flow per share
-$8.36
Book value per share
$6.91
Revenue per share
$3.4
TBVPS
$20.3
Balance sheet
Total assets
$1.22B
Total liabilities
$806.07M
Debt
$240.34M
Equity
$414.3M
Working capital
$727.66M
Liquidity
Debt to equity
0.58
Current ratio
5.21
Quick ratio
4.97
Net debt/EBITDA
-0.12
Margins
EBITDA margin
-259.1%
Gross margin
88.8%
Net margin
-284%
Operating margin
-271.7%
Efficiency
Return on assets
-44.5%
Return on equity
-100.3%
Return on invested capital
-48.1%
Return on capital employed
-52.7%
Return on sales
-270%
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

BPMC stock price

How has the Blueprint Medicines stock price performed over time
Intraday
2.52%
1 week
0.81%
1 month
16.7%
1 year
2.64%
YTD
32.89%
QTD
29.41%

Financial performance

How have Blueprint Medicines's revenue and profit performed over time
Revenue
$204.59M
Gross profit
$181.71M
Operating income
-$555.92M
Net income
-$581.08M
Gross margin
88.8%
Net margin
-284%
The operating income has grown by 14% YoY but it has contracted by 3.4% from the previous quarter
The net income has increased by 11% YoY but it has decreased by 4.2% QoQ
Blueprint Medicines's revenue has decreased by 8% YoY
The operating margin has increased by 7% YoY but it has decreased by 3.2% from the previous quarter

Growth

What is Blueprint Medicines's growth rate over time

Valuation

What is Blueprint Medicines stock price valuation
P/E
N/A
P/B
8.43
P/S
17.11
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
17.53
Blueprint Medicines's EPS has increased by 12% YoY but it has decreased by 3.9% QoQ
The price to book (P/B) is 56% higher than the last 4 quarters average of 5.4 and 45% higher than the 5-year quarterly average of 5.8
Blueprint Medicines's equity has shrunk by 53% YoY and by 20% QoQ
The P/S is 76% below the 5-year quarterly average of 70.5 but 28% above the last 4 quarters average of 13.4
Blueprint Medicines's revenue has decreased by 8% YoY

Efficiency

How efficient is Blueprint Medicines business performance
BPMC's return on equity has dropped by 71% year-on-year and by 25% since the previous quarter
The ROIC has increased by 27% YoY but it has decreased by 2.1% from the previous quarter
Blueprint Medicines's return on sales has increased by 8% YoY but it has decreased by 2.9% QoQ
The company's return on assets rose by 7% YoY but it fell by 2.5% QoQ

Dividends

What is BPMC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for BPMC.

Financial health

How did Blueprint Medicines financials performed over time
BPMC's total assets is 51% greater than its total liabilities
BPMC's total assets is down by 10% since the previous quarter but it is up by 7% year-on-year
Blueprint Medicines's current ratio has decreased by 9% from the previous quarter but it has increased by 3.8% YoY
BPMC's debt is 42% smaller than its equity
BPMC's debt has soared by 119% year-on-year
Blueprint Medicines's equity has shrunk by 53% YoY and by 20% QoQ

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.